GABA Receptor Target Identified for Alzheimer's Therapy
University of Galway researchers identified that targeting GABA signaling, specifically α5-GABA A receptors, can restore neural balance and improve memory in Alzheimer's disease models, offering a potential new therapeutic approach distinct from current excitatory-focused treatments.
Researchers at the University of Galway have identified that targeting inhibitory signaling in the brain through modulation of gamma-aminobutyric acid (GABA) receptors may help address cognitive dysfunction in Alzheimer's disease (AD), a finding that runs counter to current therapeutic approaches that focus on influencing excitatory pathways. The research, published in Neuropharmacology, demonstrates how modulation of GABA signaling can restore disrupted neural balance and improve memory-related function in AD disease models.
Alzheimer's disease is characterized by progressive cognitive impairment and is associated with hallmark pathological features including β-amyloid (Aβ) plaques and neurofibrillary tangles. In addition to these, disruption of the brain's excitatory/inhibitory (E/I) balance has gained traction as a central mechanism contributing to memory loss. Most approved therapies for AD target excitatory neurotransmitter systems such as cholinergic and glutamatergic pathways, but "the symptomatic relief provided by these therapies is only marginal, and the progression or underlying causes of the disease are not addressed," the researchers noted.
The University of Galway team focused on the inhibitory side of this balance, specifically the role of GABA, the brain's main inhibitory neurotransmitter. In AD, E/I balance becomes dysregulated with increased extracellular GABA—triggered in part by Aβ—leading to overactivation of certain GABA receptors, particularly α5-containing GABA type A receptors (α5-GABA ARs), which are abundant in the hippocampus. The result is a dampening of neuronal signaling that impairs learning and memory.
To test whether blocking α5-GABA ARs could help restore E/I balance, the team investigated α5IA, an α5-GABA AR-selective inverse agonist. α5IA works by reducing the activity of α5-GABA ARs, which decreases excess tonic inhibition. The data showed that in experimental models of AD, the compound improved long-term potentiation (LTP), a mechanism of synaptic plasticity and memory, reduced abnormal inhibitory conductance, and restored spatial memory performance.
Mechanistically, α5IA appears to act by restoring physiological levels of inhibition in the hippocampus, which is critical for memory formation. "The data presented here suggest that in both ex vivo and in vivo AD models, α5IA improves cognitive function by restoring CA1 tonic inhibition, thereby re-establishing E/I balance and ameliorating the abnormal hippocampal network activity induced by Aβ1-42," the researchers wrote.
The researchers noted limitations to their work, pointing out that while α5IA improved cognitive outcomes, it did not reverse neuronal loss in vivo, suggesting that its effects may be primarily functional rather than neuroprotective at later stages of AD. Variability in drug exposure and timing may influence outcomes, and long-term use of α5IA has been associated with safety concerns at high doses, including renal toxicity, so further research is needed to determine toxicity and dosing regimens.
The findings suggest potential to develop new AD therapies that directly target network dysfunction rather than focusing solely on amyloid accumulation or excitatory signaling. The findings could also benefit diagnostic methods, as biomarkers of inhibitory dysfunction or altered GABA signaling could help identify patients who would benefit from an approach that rebalances E/I signaling.